⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KOD News
Kodiak Sciences Inc Common Stock
IAB Connected Commerce Summit to Highlight the Path for Scalable, Sustainable Commerce Media
prnewswire.com
CRTO
DV
UBER
UL
GILD
KOD
Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
prnewswire.com
KOD
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
prnewswire.com
KOD
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
prnewswire.com
KOD
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
prnewswire.com
KOD
Kodiak Sciences Announces Proposed Public Offering of Common Stock
prnewswire.com
KOD
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
prnewswire.com
KOD
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
prnewswire.com
KOD
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
prnewswire.com
KOD
KOD